March 02, 2013 at 04:50 AM EST
Week in Review: Sinopharm Pays $252 Million for Majority Stake in Winteam Pharma
Sinopharm paid $252 million to purchase a 57% stake in China’s Winteam Pharma, a TCM maker; OrbiMed Advisors will close its second Asia healthcare private equity fund later this year, a fund that will invest mainly in China and India; China Grand Pharma announced a $20 million oncology drug JV with HuangShi Feiyun Pharma; Fosun Pharma formed a China distribution JV with Atrium Innovations, a Canadian dietary supplement company; Crystal Pharmatech of Suzhou and US-based Particle Sciences set up a CRO partnership; the SFDA proposed new drug review guidelines that will prioritize innovation and shorten review timelines; Polaris Group of San Diego will build a $50 million drug biotech manufacturing facility in Chengdu; Mindray Medical’s 2012 revenues topped $1 billion for the first time; and Pfizer received China approval for Xalkori, a treatment for NSCLC that has the ALK mutation. More details…. Stock Symbol: (HK: 0570) (HK: 00512) (SHA: 600196; HK: 2196) (TSX: ATB) (NYSE: MR) (NYSE: PFE) Share this with colleagues: // //  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here